Indeed, blunting M1R or CDGI signaling in iSPNs not only attenuated the oscillations in dendritic excitability and synaptic strength, it also had clear behavioral effects – increasing the symptomatic benefit of levodopa and attenuating on-state dyskinesia. Here, CHRM1 is linked to drug-induced dyskinesia.